Hypnogen (Zolpidem Tartrate)

Zolpidem binds selectively to the benzodiazepine site of the GABA‑A receptor complex, enhancing the inhibitory action of GABA. This increased chloride influx hyperpolarises neurons, reducing central nervous system activity and facilitating the onset and maintenance of sleep without the broader receptor activity seen with benzodiazepines.

The exact dose of Hypnogen is determined by the prescribing clinician based on the patient’s age, health status, and response to therapy. Typical adult regimens start with the lowest effective dose taken immediately before bedtime, but the prescriber sets the final regimen.

Safety data for zolpidem during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Hypnogen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with traditional benzodiazepines, zolpidem has a shorter half‑life and a more selective binding profile, which generally results in fewer next‑day residual effects. However, both classes carry risks of dependence and complex sleep behaviours, so the choice depends on individual patient factors and clinical judgment.

Hypnogen tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Hypnogen is taken orally, usually as a single dose immediately before bedtime. Patients should ensure they have a full night’s sleep opportunity (7‑8 hours) and should not consume alcohol or operate machinery after taking the medication.

Serious risks include complex sleep behaviours such as sleepwalking, sleep‑driving, or performing other activities while not fully awake, as well as severe allergic reactions, depression, suicidal thoughts, and respiratory depression when combined with other central nervous system depressants.

Hypnogen is contraindicated in patients with known hypersensitivity to zolpidem or any tablet components, those with severe hepatic impairment, and individuals who have exhibited complex sleep behaviours with prior hypnotic therapy. Caution is also advised for patients with a history of depression or substance misuse.